Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H1 2018, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperuricemia - Overview
Hyperuricemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia - Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
CymaBay Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
Nobelpharma Co Ltd
Polaris Pharmaceuticals Inc
Teijin Pharma Ltd
Hyperuricemia - Drug Profiles
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
allopurinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arhalofenate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FYU-981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HSA-Uricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2700 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPCX-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEI-A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperuricemia - Dormant Projects
Hyperuricemia - Discontinued Products
Hyperuricemia - Product Development Milestones
Featured News & Press Releases
Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricemia and Predicts Savings for NHS Scotland
May 23, 2016: Teijin Pharma’s Feburic (Febuxostat) Approved as Indication for Cancer Chemotherapy-Induced Hyperuricemia
Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
Nov 05, 2013: Teijin Pharma files patent infringement suit against Dr Reddy's
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hyperuricemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2018
Hyperuricemia - Pipeline by CymaBay Therapeutics Inc, H1 2018
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Hyperuricemia - Pipeline by Nobelpharma Co Ltd, H1 2018
Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2018
Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2018
Hyperuricemia - Dormant Projects, H1 2018
Hyperuricemia - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Hyperuricemia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
